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2012.06.0Abstract Purpose: To estimate the effect of fasting during Ramadan (the ninth lunar month) on
adherence to oral hormonal therapies (OHT) among breast cancer (BC) patients.
Patients and Methods: During Ramadan 2010, 139 BC patients were interviewed at the Egyptian
National Cancer Institute. They were asked about fasting as well as intake of OHT in Ramadan
and in the preceding month.
Results: The median age was 50 years and most patients were postmenopausal with good perfor-
mance status and non-metastatic disease. The median number of fasting days was 18% and 93% of
patients were fasting 80% or more of Ramadan. Tamoxifen and aromatase inhibitors were used in
64% and 36%, respectively. Adherence to OHT during Ramadan and its preceding month were
94.2% and 95.7%, respectively (p= 0.77). In univariate analysis, non-adherence prior to Ramadan
and shorter duration of OHT were predictors of non-adherence during Ramadan (P< 0.001,
0.003, respectively). Fasting, age, performance status, presence of metastases and type of hormonal
therapy were not good predictors of adherence.
Conclusions: While most of patients receiving OHT for BC are fasting during Ramadan, this does
not negatively impact compliance with treatment.
ª 2012 National Cancer Institute, Cairo University. Production and hosting by Elsevier B.V.
Open access under CC BY-NC-ND license.ical Oncology, National Can-
96, Egypt. Tel.: +20 235 823
0 225 328 286.
(A.A. Zeeneldin).
e National Cancer Institute,
g by Elsevier
itute, Cairo University. Production
03Introduction
Breast cancer (BC) is the commonest malignancy among females
both in developed and developing countries [1]. In Egypt, BC
represents 35% of female cancers [2]. Two thirds of BCs are po-
sitive for estrogen receptors (ER) and/or progesterone receptors
(PgR) and thus can be treated with endocrinemanipulations. ER
blockers like tamoxifen (TAM) or aromatase enzyme inhibitors
(AIs) are the most commonly used oral hormonal treatments
(OHT). However, to derive the maximum beneﬁt, these oraland hosting by Elsevier B.V. Open access under CC BY-NC-ND license.
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setting. With a duration of 1, 2 and 5 years of adjuvant TAM,
recurrences decrease by 12%, 29% and 47%, respectively [3].
As with other chronic medications [4], compliance/adher-
ence with OHT in BC is a major issue as it drops progressively
with time from 83% in ﬁrst year to 50% in the 4th year [5].
Factors associated with non-adherence include adverse side-ef-
fects, complex schedules, long treatment duration, demo-
graphic factors and ﬁnancial constrains [6]. Non-adherence
can be unintentional (e.g. when patients merely forget to take
their medications) or intentional when they choose not to take
them [7]. Intentional non-adherence can be due to lack of
information about advantages and disadvantages of treatment,
lack of obvious and immediate beneﬁts as in the adjuvant set-
ting, and seeing oneself not in need of treatment [4]. Non-
adherence can signal treatment discontinuation and both are
associated with lower 10-year survival rates (77.8% and
73.6%, respectively) than that of adherent patients (81.7%) [8].
During the ninth lunar month in the Arabic calendar (Ram-
adan), Muslims eating behavior changes as they refrain from
eating and drinking from down till sunset. Thus, oral drugs that
used to be taken during daytime have to be shifted to the night.
This change may be associated with non-adherence or discon-
tinuation that may continue afterward and have negative con-
sequences with increased recurrences and or shortened survival.
Information on compliance with oral endocrine therapies
during Ramadan is lacking. Thus we conducted this study to
estimate adherence to TAM and AIs during Ramadan com-
pared to its preceding month.
Patients and methods
This study was conducted at the out-patient clinic of the Med-
ical Oncology Department of the Egyptian National Cancer
Institute (NCI-Egypt) during Ramadan 2010. All patients con-
sented to participate in the study that was approved by the
institutional review board.
One-hundred and thirty-nine adult female patients with BC
were interviewed by the ﬁrst author (AZ) during their routine
follow up appointments. Selection criteria were a conﬁrmed
diagnosis of BC of any stage, ER and/or PR positive, receiving
OHT that is the same for at least 2 months prior to Ramadan.
They were asked how many days they were non-fasting dur-
ing Ramadan and how many days they did not receive their
OHT both during Ramadan and the preceding month. When
missing OHTs, they were further asked whether they uninten-
tionally forgot or they intentionally chose not to take them.
Data of patients’ age, type of hormonal therapy, disease stage
and aim of therapy were extracted from the patients’ ﬁles.
Outcomes were treatment adherence and predictors of non-
adherence. Adherence was calculated as the numbers of days
receiving themedications divided by the total days and expressed
as percentage. Patients were considered adherent or non-adher-
ent if they received P80% or <80% of their medications,
respectively [9]. Adherence was divided into complete or partial
if patients received 90–100% or 80–<90% of their medications.
Non-adherence was divided into intentional and unintentional.
Statistical analysis
All data were analyzed using SPSS v15 software (Chicago,
USA). The dependent variable ‘adherence during Ramadan’was then subjected to Chi-squared test analysis to identify
any association with relevant factors (age, performance status,
presence of metastases, type of hormonal therapy and adher-
ence in the month preceding Ramadan) which were then en-
tered into a logistic regression analysis.Results
The study included 139 female patients with BC. The median
age was 50 years (Table 1). Most patients were postmeno-
pausal (60%) with good performance status (PS 0-1 in 80%)
and non-metastatic disease (81%). The median number of fast-
ing days was 18. OHT was given as adjuvant therapy in 81%
and TAM was given in 64% while AIs in 36%. Fasting 80%
or more of Ramadan was encountered in 93% of patients.
One ﬁfth of the patients presented with metastatic disease
and most of them had single metastasis. Almost half of the pa-
tients were receiving OHT for a duration up to 2 years.
Adherence to OHT during Ramadan was 94.2% compared
to 95.7% prior to Ramadan (p= 0.77) with higher but insig-
niﬁcant rate of intentional non-adherence prior to Ramadan
(P= 0.92, Table 2). Adherence was complete in 97% of pa-
tients both during and before Ramadan (P= 0.74). Six out
of the eight patients recognized as non-adherent to OHT dur-
ing Ramadan were also non-adherent in the preceding month.
Six of the eight non-adherent patients during Ramadan were
on TAM and four of them (67%) intentionally opted not to
take the drug because of side effects that were mostly hot
ﬂushes and epigastric pains. All non-adherences with AIs were
unintentional and mostly related to missing their prescriptions.
Age, performance status, presence of metastases, type and
duration of hormonal therapy and history of adherence in
the month preceding Ramadan were assessed for their effects
on adherence to OHT during Ramadan (Table 3). Non-adher-
ence to OHT prior to Ramadan and a shorter duration of
OHT (62 years) were associated with non-adherence to OHT
during Ramadan (p< 0.001 and 0.003, respectively). This
was shown only in univariate analysis and was lost in multivar-
iate analysis.Discussion
Long-term daily OHT in BC reduces recurrences and increases
survival. However, adherence to these medications is essential
to derive the mentioned beneﬁts [10]. While adherence to OHT
in BC patients was assessed in many trials, little is known
about adherence during the fasting month of Ramadan when
eating behaviors of fasting patients change with a possibility
of increased non-adherence.
This study assessed short term adherence to OHTG over a
period of two months; Ramadan and its preceding month.
Thus it differs from other studies [5,6,9] that assessed long
term adherence. We assessed adherence among patients regu-
larly attending their routine appointments, thus we could not
assess the fraction that opted to permanently discontinue their
medications as those would not be accessible. Short-term
compliance, as in our study, needs to be correlated with long
term adherence and this issue needs further attention and
research.
Given the high illiteracy rates among Egyptian females [11],
we felt that a self-administered questionnaire would be difﬁcult
Table 2 Adherence to oral hormonal therapy in 139 breast cancer patients during Ramadan and prior to Ramadan.
Ramadann (%) Prior to Ramadann (%) P value
Adherence to OHT 139 (100) 139 (100)
Adherenta 131 (94.2) 133 (95.7)
Non-adherenta 8 (5.8) 6 (4.3) 0.77
Non-adherence to OHT 8 (100) 6 (100)
Intentional 4/8 (50) 4/6 (67)
Non-intentional 4/8 (50) 2/6 (33) 0.92
Adherence to OHT 131 (100) 133 (100)
Completeb 127 (97) 129 (97)
Partialb 4 (3) 4 (3) 0.74
OHT: oral hormonal therapy.
a Patients were considered adherent or non-adherent if they received P80% or <80% of their medications.
b Adherence was divided into complete or partial if patients received 90–100% or 80–<90% of their medications.
Table 1 Patients’ characteristics of 139 breast cancer patients receiving hormonal therapy during Ramadan.
Characteristic Number (139) Percentage (100)
Age: median (IQR) years 50 (43–60)
Fasting days: median (range) 18 (4–30)
Menopausal state Premenopausal 55 39.6
Postmenopausal 84 60.4




Disease stage Non-metastatic 112 80.6
Single metastases 22 15.8
Multiple metastases 5 3.6
Metastatic sites Bone/Soft tissue 18 12.9
Visceral/CNS 11 7.9
Hormonal therapy Adjuvant 112 80.6
Palliative 27 19.4
Duration of hormonal therapy Up to 1 year 32 23
>1–2 years 36 25.9
>2–3 years 23 16.5
>3–4 years 35 25.2
>4–5 years 13 9.4
Type of hormonal therapy Tamoxifen 89 64
Letrozole (Femara) 29 20.9
Exemestane (Aromazin) 10 7.2
Anastrazole (Arimidex) 11 7.9
Chemotherapy None 20 14.4
Adjuvant/Neoadjuvant 107 77
Palliative 12 8.6
Radiotherapy No 28 20
Yes 111 80
Surgery None 12 8.6
MRM 95 68.3
BCS 32 23
IQR: interquartile range, ECOG: eastern cooperative oncology group, CNS: central nervous system, MRM: modiﬁed radical mastectomy, BCS:
breast conserving surgery.
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from exaggeration of adherence claims to satisfy the inter-viewer or to obviate a possible blame [10]. However, the inter-
view was conducted in friendly circumstances to allow patients
Table 3 Univaraite and multivariate analyses of factors that may affect adherence to oral hormonal therapy in breast cancer patients
during Ramadan.
Factor Number Adherentn (%) Non-adherent n (%) Univariate P value Multivariate p value
Age
<65 years 129 121 (93.8%) 8 (6.2%)
P65 years 10 10 (100%) – 0.92 0.99
Performance status
0–1 111 105 (95%) 6 (5%)
>1 28 26 (93%) 2 (7%) 0.72 0.99
Metastases
No 112 106 (95%) 6 (5%)
Yes 27 25 (93%) 2 (7%) 0.68 1
Hormonal therapy
Tamoxifen 89 83 (93%) 6 (7%)
Aromatase inhibitors 50 48 (96%) 2 (4%) 0.51 0.99
Duration of hormonal therapy
0–2 years 68 60 (88) 8 (12)
>2 years 71 71 (100) – 0.003 0.99
Adherence prior to Ramadan
Intake of P80% of OHT 133 131 (99%) 2 (1%)
Intake of <80% of OHT 6 – 6 (100%) <.001 0.99
Fasting
P80% of Ramadan days 124 116 (93%) 8 (7%)
<80% of Ramadan days 15 8 (100%) – 0.311 1
136 A.A. Zeeneldin et al.reveal as much normal information as possible. Patients were
reassured that their answers, whatever they are, will never af-
fect their treatments negatively.
The majority of patients (94%) were adherent to their OHT
during Ramadan which is slightly (and insigniﬁcantly) lower
than the non-fasting months (96%). Patients usually change
the timing to match the change in the eating patterns, i.e. in-
stead of taking the drugs during day time, they shift this to
the night time where eating and drinking are religiously al-
lowed. Maintaining adherence to OHT during Ramadan is
facilitated by the non-complex schedules of these medications
and the relative lack of their side effects [6]. Moreover as the
ﬁrst meal after a full-day fast is usually indoors gathering all
family members, patients will easily access their medications
and receive reminders and support from family.
The rates of adherence to OHT in our study are similar to
those reported by other researchers in the short-term [6,11,12].
This reﬂects the short duration of the study and hence the ease
of recalling adherence information by the patients. Also, many
of the negative predictors of poor adherence are obviated in
the current study [4]. The negative impact of low socioeconomic
on adherence in the current study was abolished as most aspects
of themedical care of the interviewedpatients (includingmedical
exams, laboratory and radiologic investigations as well as med-
ications) were provided free of charge. Moreover, the crowded
clinics and the longwaiting time allows a signiﬁcant time for con-
tact with and observation of other patients. This might enhance
compliance through something similar to psychological group
support techniques. Patients on OHT may recall their unfavor-
able experiences with chemotherapy and realized how other pa-
tients do poorly upon relapse and these two factors provide an
incentive for adherence to avoid getting relapse and further
receiving chemotherapy.
Adherence in themonth preceding Ramadanwas signiﬁcantly
associated with adherence during Ramadan (P< 0.001). This
may reﬂect the patient personality; as compliers prior to Rama-
dan will mostly remain compliant during Ramadan. A shorterduration of OHT was associated with non-adherence during
Ramadan (p< 0.003). While this contradicts with studies that
showed that compliance decreases with the longer duration of
OHT use, it reﬂects a fact that patients who are using OHT for
a longer time are more accustomed to the drugs and less likely
to drop them during Ramadan. Age was not a factor as most
of our patients (90%) were below the age of 65. Similarly per-
formance status (PS) had no inﬂuence as most of the patients
(80%) were in the favorable group (PS 0–1) and only a minority
(4%) had a PS of 3. Type of hormonal therapy had no inﬂuence
on adherence. This may be explained by simple administration
schedule (once daily) of both TAM and AIs. Metastases had no
inﬂuence onAdherence. This is becausemost of those patients eli-
gible for OHT either had bone metastases or slowly progressive
visceral disease. Thus most of them are stable for long periods.
Similar to previous studies [4,13,14], adherence to OHT in
our study did not differ with TAM or AIs. The lower adher-
ence rates reported by Ziller et al. [9] with AIs compared to
TAM were debated mostly with the small numbers included
in their study [5].
Intentional non-adherence was insigniﬁcantly lower during
Ramadan compared to its preceding month (50% vs. 67%).
Intentional non-adherences in Ramadan and the prior month
were related to TAM and its side-effects. Those non-adherent
patients preferred to continue fasting than getting the treat-
ments. However, the differences were statistically insigniﬁcant
and the absolute numbers were small.
In conclusion, Egyptian BC patients receiving OHT have
high rates of short-term adherence to these medications. Fast-
ing does not appear to decrease this adherence and thus, in the
absence of a contraindication, patients should not be discour-
aged to fast if they wish.Conﬂict of interest statement
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